Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Kluczowe dokumenty

Wyświetl całą dokumentację

B-001

Supelco

Benzoylecgonine-d3 solution

100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Synonim(y):

Benzoylecgonine-N-methyl-d3 solution

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Wzór empiryczny (zapis Hilla):
C16D3H16NO4
Numer CAS:
115732-68-8
Masa cząsteczkowa:
292.34
Numer WE:
200-659-6
Numer MDL:
MFCD00058542
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
329773089
NACRES:
NA.24

klasa czystości

certified reference material

Poziom jakości

300

Formularz

liquid

Właściwości

SNAP-N-SPIKE®, SNAP-N-SHOOT®

opakowanie

ampule of 1 mL

producent / nazwa handlowa

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IB (Portugal)

stężenie

100 μg/mL in methanol

metody

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Zastosowanie

forensics and toxicology

Format

single component solution

przesunięcie masy

M+3

Warunki transportu

wet ice

temp. przechowywania

−20°C

ciąg SMILES

[2H]C([2H])([2H])N1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)c3ccccc3)C(O)=O

InChI

1S/C16H19NO4/c1-17-11-7-8-12(17)14(15(18)19)13(9-11)21-16(20)10-5-3-2-4-6-10/h2-6,11-14H,7-9H2,1H3,(H,18,19)/t11-,12+,13-,14+/m0/s1/i1D3

Klucz InChI

GVGYEFKIHJTNQZ-GZBWLTEMSA-N

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Powiązane kategorie

Opis ogólny

A stable-labeled internal standard suitable for isotope dilution methods or benzoylecgonine testing in urine, saliva, blood, or hair by GC/MS or LC/MS for applications in clinical toxicology, urine drug testing, pain prescription monitoring or forensic analysis. Benzoylecgonine is the primary metabolite of cocaine and a major biomarker for determination of cocaine use.

Zastosowanie


  • Mass Spectrometry Internal Standard: Benzoylecgonine-d₃ is utilized as a robust internal standard in mass spectrometry to enhance the accuracy and precision of quantitative analysis of cocaine metabolites in clinical toxicology studies, providing crucial data for forensic and clinical applications (Handley et al., 2019).

  • Forensic Toxicology Research: The application of Benzoylecgonine-d₃ in gas chromatography-mass spectrometry (GC-MS) underscores its value in the forensic analysis of cocaine and its metabolites in biological samples, offering reliable quantification essential for legal and medical investigations (Fleming et al., 2010).

  • LC-MS/MS Quantitative Analysis: Benzoylecgonine-d₃ serves as a critical component in developing validated LC-MS/MS methodologies for drug testing, ensuring the traceability and reproducibility required in doping control and therapeutic drug monitoring (Lin et al., 2001).

  • Pharmacokinetic Studies: The use of stable isotope-labeled Benzoylecgonine-d₃ enables detailed pharmacokinetic studies, helping to understand the metabolism of cocaine and assess the impact of various physiological and pathological conditions on drug metabolism (Lin et al., 2001).

  • Drug Metabolism Analysis: In forensic science, Benzoylecgonine-d₃ is crucial for developing sensitive and selective analytical methods for detecting and quantifying cocaine use, supporting both clinical diagnostics and legal proceedings (Hall et al., 1999).


Informacje prawne

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Ta strona może zawierać tekst przetłumaczony maszynowo.

produkt powiązany

Numer produktu
Opis
Cennik

B-004

Benzoylecgonine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-007

Benzoylecgonine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-008

Benzoylecgonine-d3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-013

Benzoylecgonine-D8 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-014

Benzoylecgonine-D8 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

C-009

Cocaethylene-D3 solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

C-010

Cocaethylene solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

C-024

Cocaethylene-D8 solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

C-088

Cocaine Multi-component Mixture solution, 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

H-017

m-Hydroxybenzoylecgonine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-135

p-Hydroxycocaine hydrochloride solution, 1 mg/mL in acetonitrile (as free base), certified reference material, ampule of 1 mL, Cerilliant®

Hasło ostrzegawcze

Danger

Zwroty wskazujące rodzaj zagrożenia

H225,H301 + H311 + H331,H370

Klasyfikacja zagrożeń

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organy docelowe

Eyes,Central nervous system

Kod klasy składowania

3 - Flammable liquids

Klasa zagrożenia wodnego (WGK)

WGK 2

Temperatura zapłonu (°F)

49.5 °F - closed cup

Temperatura zapłonu (°C)

9.7 °C - closed cup

Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

Przepraszamy, ale COA dla tego produktu nie jest aktualnie dostępny online.

Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Klienci oglądali również te produkty

Slide 1 of 4

1 of 4

Cocaine Multi-component Mixture solution 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-088

Cocaine Multi-component Mixture solution

Codeine-D3 solution 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-005

Codeine-D3 solution

Cocaine-D3 solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-014

Cocaine-D3 solution

Cannabidiol solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-045

Cannabidiol solution

Oruc Allahverdiyev et al.
Turkish journal of medical sciences, 45(6), 1380-1389 (2016-01-19)
Treating animals repeatedly with intermittent and increasing morphine doses has been suggested to allow some withdrawal during each dosing interval, which causes repeated stress. The present study aimed to test this hypothesis and assess sex-related differences in withdrawal signs and
James Brian McAlvin et al.
Investigative ophthalmology & visual science, 56(6), 3820-3826 (2015-06-13)
Amino-amide or amino-ester local anesthetics, which are currently used for topical ocular anesthesia, are short acting and may delay corneal healing with long-term use. In contrast, site 1 sodium channel blockers (S1SCBs) are potent local anesthetics with minimal adverse tissue
Kalpashri Kesavan et al.
Respiratory physiology & neurobiology, 201, 93-100 (2014-07-11)
Sedative-analgesics are often given to newborn infants and are known to affect many components of the autonomic nervous system. While morphine is most frequently used, α-2 adrenergic receptor agonists are being increasingly used in this population. Alpha-2 adrenergic receptors agonists
Paula E Park et al.
Addiction biology, 20(2), 275-284 (2013-12-18)
Opioids represent effective drugs for the relief of pain, yet chronic opioid use often leads to a state of increased sensitivity to pain that is exacerbated during withdrawal. A sensitization of pain-related negative affect has been hypothesized to closely interact
Craige C Wrenn et al.
Neuroscience letters, 585, 109-113 (2014-11-30)
Fragile X syndrome (FXS), a disorder caused by a mutation in the FMR1 gene, is often associated with Attention Deficit Hyperactivity Disorder (ADHD). Common treatments for the hyperactivity often seen in ADHD involve the use of stimulants and α2-adrenergic agonists.
Wyświetl wszystkie powiązane dokumenty

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej